Jun 04, 2026
EULAR 2026 – IMP761, a novel immunosuppressive LAG-3 agonist antibody in the clinic
May 31, 2026
ASCO 2026 – Eftilagimod alfa, an APC activator via MHC class II, induced lymphocyte activation linked to improved survival in metastatic cancer patients
Feb 20, 2026
Immutep Corporate Presentation
Dec 02, 2025
SABCS 2025 – Optimal biological dose of eftilagimod alpha, a soluble LAG-3 protein, in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003
Nov 13, 2025
CTOS 2025 Annual Meeting – EFTISARC-NEO trial with neoadjuvant eftilagimod alfa (Soft Tissue Sarcoma)
Oct 19, 2025
ESMO Congress 2025 – EFTISARC-NEO (Soft Tissue Sarcoma)
Oct 18, 2025
ESMO Congress 2025 – INSIGHT-003 (First Line Non-Small Cell Lung Cancer)
ESMO Congress 2025 – TACTI-004 (First Line Non-Small Cell Lung Cancer)
Dec 12, 2024
ESMO Immuno-Oncology 2024 – TACTI-003, Cohort B (Metastatic Head and Neck Squamous Cell Carcinoma)
Nov 22, 2024
2024 AGM CEO Presentation
Nov 13, 2024
CTOS 2024 Annual Meeting – EFTISARC-NEO trial of neoadjuvant soluble LAG-3 protein (Soft Tissue Sarcoma)
Sep 15, 2024
ESMO Congress 2024 – TACTI-003, Cohort A (Head and Neck Squamous Cell Carcinoma)
